Konstantinos C Siontis

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5582060/publications.pdf

Version: 2024-02-01

86 papers 3,141 citations

257450 24 h-index 53 g-index

87 all docs

87 docs citations

87 times ranked 4536 citing authors

#	Article	IF	CITATIONS
1	Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. Circulation, 2018, 138, 1519-1529.	1.6	359
2	Artificial intelligence-enhanced electrocardiography in cardiovascular disease management. Nature Reviews Cardiology, 2021, 18, 465-478.	13.7	298
3	Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis. Lancet, The, 2015, 386, 655-664.	13.7	261
4	Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large Highâ€Risk Population. Journal of the American Heart Association, 2014, 3, e001002.	3.7	200
5	Overlapping meta-analyses on the same topic: survey of published studies. BMJ, The, 2013, 347, f4501-f4501.	6.0	184
6	Detection of Hypertrophic Cardiomyopathy Using a Convolutional Neural Network-Enabled Electrocardiogram. Journal of the American College of Cardiology, 2020, 75, 722-733.	2.8	183
7	Artificial intelligence–enabled electrocardiograms for identification of patients with low ejection fraction: a pragmatic, randomized clinical trial. Nature Medicine, 2021, 27, 815-819.	30.7	154
8	Women with hypertrophic cardiomyopathy have worse survival. European Heart Journal, 2017, 38, 3434-3440.	2.2	147
9	Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. Heart Rhythm, 2016, 13, 1418-1424.	0.7	123
10	Artificial Intelligence–Electrocardiography to Predict Incident Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e009355.	4.8	68
11	Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2016, 17, 604-610.	1.2	63
12	Association of preprocedural cardiac magnetic resonance imaging with outcomes of ventricular tachycardia ablation in patients with idiopathic dilated cardiomyopathy. Heart Rhythm, 2017, 14, 1487-1493.	0.7	61
13	Bileaflet Mitral Valve Prolapse and Risk of Ventricular Dysrhythmias and Death. Journal of Cardiovascular Electrophysiology, 2016, 27, 463-468.	1.7	59
14	When to replicate systematic reviews of interventions: consensus checklist. BMJ, The, 2020, 370, m2864.	6.0	58
15	Diagnostic tests often fail to lead to changes in patient outcomes. Journal of Clinical Epidemiology, 2014, 67, 612-621.	5.0	55
16	Generalizability of the CASTLE-AF trial: Catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm, 2020, 17, 1057-1065.	0.7	54
17	Correlation between computer tomographyâ€derived scar topography and critical ablation sites in postinfarction ventricular tachycardia. Journal of Cardiovascular Electrophysiology, 2018, 29, 438-445.	1.7	52
18	Value of cardiac magnetic resonance imaging and programmed ventricular stimulation in patients with frequent premature ventricular complexes undergoing radiofrequency ablation. Heart Rhythm, 2017, 14, 1695-1701.	0.7	45

#	Article	IF	Citations
19	Replication, Duplication, and Waste in a Quarter Million Systematic Reviews and Meta-Analyses. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e005212.	2.2	45
20	Radiofrequency Ablation Versus Antiarrhythmic Drug Therapy for AtrialÂFibrillation. JACC: Clinical Electrophysiology, 2016, 2, 170-180.	3.2	44
21	Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Disease Other Than Significant Mitral Stenosis and Mechanical Valves. Circulation, 2017, 135, 714-716.	1.6	42
22	Apical vs. non-apical right ventricular pacing in cardiac resynchronization therapy: a meta-analysis. Europace, 2015, 17, 1259-1266.	1.7	41
23	How Will Machine Learning Inform the Clinical Care of Atrial Fibrillation?. Circulation Research, 2020, 127, 155-169.	4.5	35
24	Detection of hypertrophic cardiomyopathy by an artificial intelligence electrocardiogram in children and adolescents. International Journal of Cardiology, 2021, 340, 42-47.	1.7	35
25	Inappropriate Dosing of Direct Oral Anticoagulants in Patients with Atrial Fibrillation. American Journal of Cardiology, 2021, 144, 52-59.	1.6	27
26	Association of New-Onset Atrial Fibrillation After Noncardiac Surgery With Subsequent Stroke and Transient Ischemic Attack. JAMA - Journal of the American Medical Association, 2020, 324, 871.	7.4	25
27	Risk stratification in patients with frequent premature ventricular complexes in the absence of known heart disease. Heart Rhythm, 2020, 17, 423-430.	0.7	24
28	Outcomes Associated With Catheter Ablation of Ventricular Tachycardia in Patients With Cardiac Sarcoidosis. JAMA Cardiology, 2022, 7, 175.	6.1	22
29	Effect of Body Mass Index on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2018, 121, 100-106.	1.6	21
30	Batch enrollment for an artificial intelligence-guided intervention to lower neurologic events in patients with undiagnosed atrial fibrillation: rationale and design of a digital clinical trial. American Heart Journal, 2021, 239, 73-79.	2.7	21
31	Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006515.	2.2	20
32	Postinfarction Myocardial Calcifications on Cardiac Computed Tomography. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007023.	4.8	19
33	Pharmacoinvasive and Primary Percutaneous Coronary Intervention Strategies in ST-Elevation Myocardial Infarction (from the Mayo Clinic STEMI Network). American Journal of Cardiology, 2016, 117, 1904-1910.	1.6	17
34	Thromboembolic prophylaxis protocol with warfarin after radiofrequency catheter ablation of infarctâ€related ventricular tachycardia. Journal of Cardiovascular Electrophysiology, 2018, 29, 584-590.	1.7	17
35	Electrogramâ€guided endomyocardial biopsy yield in patients with suspected cardiac sarcoidosis and relation to outcomes. Journal of Cardiovascular Electrophysiology, 2021, 32, 2486-2495.	1.7	16
36	Magnetic Resonance Mapping of Catheter Ablation Lesions After Post-Infarction Ventricular Tachycardia Ablation. JACC: Cardiovascular Imaging, 2021, 14, 588-598.	5. 3	15

#	Article	IF	CITATIONS
37	Prognostic Impact of the Timing of Recurrence of Infarct-Related Ventricular Tachycardia After Catheter Ablation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	14
38	Arrhythmias in Cardiac Sarcoidosis Bench to Bedside. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009203.	4.8	14
39	Intervention to Reduce Inappropriate Ionized Calcium Ordering Practices: A Quality-Improvement Project., 2015, 19, 49-51.		13
40	Atrial Fibrillation Pathophysiology and Prognosis. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	11
41	Stroke Prophylaxis in Patients with Atrial Fibrillation and End-Stage Renal Disease. Journal of Clinical Medicine, 2020, 9, 123.	2.4	11
42	Prognostic value of positron emission tomography myocardial perfusion imaging beyond traditional cardiovascular risk factors: Systematic review and meta-analysis. IJC Heart and Vasculature, 2015, 6, 54-59.	1.1	9
43	Screening and management of atrial fibrillation in primary care. BMJ, The, 2021, 373, n379.	6.0	9
44	The precordial R′ wave: A novel discriminator between cardiac sarcoidosis and arrhythmogenic right ventricular cardiomyopathy in patients presenting with ventricular tachycardia. Heart Rhythm, 2021, 18, 1539-1547.	0.7	9
45	Periprocedural Anticoagulation Management for Atrial Fibrillation Ablation: Current Knowledge and Future Directions. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 3.	0.9	8
46	Silent and nonâ€silent thromboembolic events after ventricular tachycardia ablation: Modifiable risk with postprocedure anticoagulation?. Journal of Cardiovascular Electrophysiology, 2019, 30, 1197-1199.	1.7	8
47	Multimodal Interventions to Increase Anticoagulant Utilization in Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006418.	2.2	8
48	Comparison of the longevity of implantable cardioverter-defibrillator devices by different manufacturers. International Journal of Cardiology, 2014, 175, 380-382.	1.7	6
49	Atrial Fibrillation and Obstructive Sleep Apnea. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	4.8	6
50	Cavotricuspid isthmus ablation for atrial flutter: Anatomic challenges and troubleshooting. HeartRhythm Case Reports, 2020, 6, 115-120.	0.4	6
51	The Role of Artificial Intelligence in Arrhythmia Monitoring. Cardiac Electrophysiology Clinics, 2021, 13, 543-554.	1.7	6
52	Use of Artificial Intelligence Tools Across Different Clinical Settings. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008153.	2.2	6
53	Development and validation pathways of artificial intelligence tools evaluated in randomised clinical trials. BMJ Health and Care Informatics, 2021, 28, e100466.	3.0	6
54	Artificial Intelligence–Enabled Electrocardiogram for Atrial Fibrillation Identifies Cognitive Decline Risk and Cerebral Infarcts. Mayo Clinic Proceedings, 2022, 97, 871-880.	3.0	6

#	Article	IF	Citations
55	Prevention of Atrioesophageal Fistula After Catheter Ablation. JACC: Clinical Electrophysiology, 2017, 3, 1155-1157.	3.2	5
56	Targeting Noninducible Clinical Ventricular Tachycardias in Patients With Prior Myocardial Infarctions Based on Stored Electrograms. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e006978.	4.8	5
57	Risk stratification in patients with nonischemic cardiomyopathy and ventricular arrhythmias based on quantification of intramural delayed enhancement on cardiac magnetic resonance imaging. Journal of Cardiovascular Electrophysiology, 2020, 31, 1762-1769.	1.7	5
58	Factors predictive for delayed enhancement in cardiac resonance imaging in patients undergoing catheter ablation of premature ventricular complexes. Heart Rhythm O2, 2021, 2, 64-72.	1.7	5
59	Characteristics and outcomes of ventricular tachycardia and premature ventricular contractions ablation in patients with prior mitral valve surgery. Journal of Cardiovascular Electrophysiology, 2022, 33, 274-283.	1.7	5
60	QRS complex maximum deflection index in aortic cusp premature ventricular complexes. IJC Heart and Vasculature, 2015, 7, 6-8.	1.1	4
61	Atrial fibrillation in heart failure syndromes: does it matter more in some than in others?. European Heart Journal, 2018, 39, 4285-4286.	2.2	4
62	PROTOCOL: When and how to replicate systematic reviews. Campbell Systematic Reviews, 2020, 16, e1087.	3.0	4
63	Impact of Intramural Scar on Mapping and Ablation of Premature Ventricular Complexes. JACC: Clinical Electrophysiology, 2021, 7, 733-741.	3.2	4
64	Significance of clinical ventricular tachycardias induced by antitachycardia pacing in patients with prior myocardial infarction. Heart Rhythm, 2019, 16, 544-550.	0.7	3
65	Arrhythmia exacerbation after post-infarction ventricular tachycardia ablation: prevalence and prognostic significance. Europace, 2020, 22, 1680-1687.	1.7	3
66	Atrial Fibrillation and Cancer. JACC: CardioOncology, 2021, 3, 233-235.	4.0	3
67	Catheter ablation of ventricular tachycardia in patients with postinfarction left ventricular aneurysm. Journal of Cardiovascular Electrophysiology, 2021, 32, 3156-3164.	1.7	3
68	Hybrid Catheter-Based and Surgical Techniques for Ablation of Ventricular Arrhythmias. Arrhythmia and Electrophysiology Review, 2020, 9, 97-103.	2.4	3
69	Safety of catheter ablation in obese patients: Less complicated than you think. Journal of Cardiovascular Electrophysiology, 2022, 33, 664-666.	1.7	3
70	Ventricular Tachycardia Targeted in the Aortic Sinuses of Valsalva in Patients with Prior Myocardial Infarction. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	3
71	Reply to letter by Ferrante di Ruffano et al.: Patient outcomes in randomized comparisons of diagnostic tests are still the ultimate judge. Journal of Clinical Epidemiology, 2016, 69, 267-268.	5.0	2
72	Novel Interventional Strategies for the Treatment of Atrial Fibrillation. Arrhythmia and Electrophysiology Review, 2016, 5, 50.	2.4	2

#	Article	IF	CITATIONS
73	On-treatment follow-up in real-world studies of direct oral anticoagulants in atrial fibrillation: Association with treatment effects. IJC Heart and Vasculature, 2022, 40, 101024.	1.1	2
74	Intra-procedural anticoagulation protocols for left-sided cardiac ablations: Striking a balance between risk and benefit. Indian Pacing and Electrophysiology Journal, 2016, 16, 179-180.	0.6	1
75	FIRE or ICE for paroxysmal atrial fibrillation?—perspectives from the largest randomized evaluation of cryoballoon and radiofrequency ablation to date. Journal of Thoracic Disease, 2017, 9, 419-422.	1.4	1
76	Down but not out—addressing the scourge of late pulmonary vein reconnection. Journal of Cardiovascular Electrophysiology, 2019, 30, 824-826.	1.7	1
77	Natural language processing of implantable cardioverter-defibrillator reports in hypertrophic cardiomyopathy: A paradigm for longitudinal device follow-up. Cardiovascular Digital Health Journal, 2021, 2, 264-269.	1.3	1
78	Abstract 17268: Echocardiographic Predictors of Cardiopulmonary Exercise Test Performance in Hypertrophic Cardiomyopathy. Circulation, 2014, 130, .	1.6	1
79	Prediction of Major Clinical Endpoints in Nonischemic Cardiomyopathy. JACC: Clinical Electrophysiology, 2015, 1, 408-410.	3.2	0
80	Cardiac memory for the clinical electrophysiologist. Journal of Cardiovascular Electrophysiology, 2019, 30, 2140-2143.	1.7	0
81	Response by Siontis et al to Letter Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States― Circulation, 2019, 139, 1563-1564.	1.6	0
82	Postoperative Atrial Fibrillation After Noncardiac Surgery and Stroke—Reply. JAMA - Journal of the American Medical Association, 2021, 325, 187.	7.4	0
83	Pushing the Limits of the ECG. JACC: Cardiovascular Imaging, 2021, , .	5.3	O
84	Abstract 16775: Body Mass Index Predicts Exercise Capacity in Patients With Hypertrophic Cardiomyopathy. Circulation, 2014, 130, .	1.6	0
85	Vein of Marshall alcohol ablationÂfor dormant pulmonary vein conduction: A case report. Journal of Cardiovascular Electrophysiology, 2022, , .	1.7	0
86	Abstract 10726: Cardiac Resynchronization Therapy Response in Cardiac Sarcoidosis. Circulation, 2021, 144, .	1.6	0